Schulkind J, et al. - Researchers tested if recruitment and successful treatment are possible for people who actively inject drugs through a community needle and syringe programme (NSP). They also sought the re-infection rates in this community. Recruitment of 105 hepatitis C virus (HCV) RNA positive participants (mean age 34.0 years) from the largest NSP in Dundee was performed over 42 months. Treatment was initiated by 94/105 individuals [71.3% (61/94) male]. Patients with genotype 1 (G1) (n = 37) were treated with peg-interferon+ribavirin+Simepravir/Telaprevir and those with Genotype 2/3 (G2/3) (n = 57) received peg-interferon+ribavirin. No difference in sustained virological response at 12 weeks (SVR-12) rates was evident by genotype: 81.0% (30/37) for G1 and 82.5% (47/55) for G2/3. At 18 months post-treatment, reinfection was noted in 15/77 participants. Findings thus demonstrate the possibility of delivering successful HCV treatment to the target population of treatment as prevention strategies. The higher rates of re-infection than existing estimates among PWID emphasize persuing scaling-up of HCV treatment alongside a comprehensive programme of harm reduction interventions to help minimize re-infection and reduce HCV transmission.